Successfully completed a $60 million IPO with strong institutional backing (Guggenheim Securities as sole book-running manager), experienced management team with deep biotech expertise, and clear strategic focus on high-growth healthcare and biotechnology sectors. The company has secured capital and is positioned to pursue acquisitions in promising life sciences areas.
Also mentions JATT
Articles that tag JATT but are mainly about other companies.
None recently.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology